Connect with us


Changes at the top at Haemonetics

Avatar photo



Healthcare innovation firm Haemonetics Corporation has appointed a new executive vice president and chief financial officer (CFO).

James D’Arecca will take up both roles,  overseeing the company’s treasury, controllership and accounting, investor relations, tax, information technology, and financial planning and analysis functions.

D’Arecca has nearly 30 years of experience in finance leadership and strategy. Since June 2020, he has served as CFO of TherapeuticsMD, a women’s healthcare company.

Previously, he was senior vice president and chief accounting Officer at Allergan plc for nearly seven years until its merger with AbbVie, Inc. in May 2020, and earlier in his career he held finance and business development positions at Bausch + Lomb, Merck & Co., Inc., and Schering-Plough.

He began his career with PricewaterhouseCoopers, where he had an industry focus on pharmaceuticals, medical devices, and consumer products.

D’Arecca succeeds William Burke, who last year shared his decision to retire as the company’s CFO. Burke will remain with Haemonetics in an advisory role to June 30.

“James brings to Haemonetics substantial experience in financial leadership for prominent global healthcare organisations,” the firm said. “His expertise will play a significant role in supporting our company’s transformational growth objectives and delivering long-term value for our stakeholders. We are excited to welcome him to Haemonetics to lead our global Finance team.”

D’Arecca said: “Haemonetics is recognised and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the company continue to achieve strong results, accelerate growth, and expand its impact throughout the world.”

Haemonetics is a global healthcare company which provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare.

Its technology addresses several medical markets including blood and plasma component collection, the surgical suite and hospital transfusion services.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories